Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 129

1.

How Do We Respond to Men with BRCA Mutations when They Ask About Prostate Cancer?

Karzai F, Madan RA, Dahut WL.

Eur Urol. 2020 Jan;77(1):36-37. doi: 10.1016/j.eururo.2019.10.001. Epub 2019 Oct 30. No abstract available.

PMID:
31676126
2.

Natural history and imaging in men with high genetic risk for developing prostate cancer.

Dahut WL, Couvillon A, Pinto PA, Turkbey B, Karzai F.

Can J Urol. 2019 Oct;26(5S2):7-8.

3.

Impact of Anatomic Location of Bone Metastases on Prognosis in Metastatic Castration-Resistant Prostate Cancer.

Roth AR, Harmon SA, Perk TG, Eickhoff J, Choyke PL, Kurdziel KA, Dahut WL, Apolo AB, Morris MJ, Perlman SB, Liu G, Jeraj R.

Clin Genitourin Cancer. 2019 Aug;17(4):306-314. doi: 10.1016/j.clgc.2019.05.013. Epub 2019 May 27.

PMID:
31221545
4.

A Case of Anti-PD-L1-associated Remitting Seronegative Symmetric Synovitis With Pitting Edema.

Redman JM, Rhea LP, Cordes L, Owens H, Madan RA, Bilusic M, Gulley JL, Lee JM, Dahut WL, Karzai F.

Clin Genitourin Cancer. 2019 Jun;17(3):e549-e552. doi: 10.1016/j.clgc.2019.02.005. Epub 2019 Feb 14. No abstract available.

PMID:
30850338
5.

A comparison of prostate cancer bone metastases on 18F-Sodium Fluoride and Prostate Specific Membrane Antigen (18F-PSMA) PET/CT: Discordant uptake in the same lesion.

Harmon SA, Mena E, Shih JH, Adler S, McKinney Y, Bergvall E, Mehralivand S, Sowalsky AG, Couvillon A, Madan RA, Gulley JL, Eary J, Mease RC, Pomper MG, Dahut WL, Turkbey B, Lindenberg L, Choyke PL.

Oncotarget. 2018 Dec 28;9(102):37676-37688. doi: 10.18632/oncotarget.26481. eCollection 2018 Dec 28.

6.

Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations.

Karzai F, VanderWeele D, Madan RA, Owens H, Cordes LM, Hankin A, Couvillon A, Nichols E, Bilusic M, Beshiri ML, Kelly K, Krishnasamy V, Lee S, Lee MJ, Yuno A, Trepel JB, Merino MJ, Dittamore R, Marté J, Donahue RN, Schlom J, Killian KJ, Meltzer PS, Steinberg SM, Gulley JL, Lee JM, Dahut WL.

J Immunother Cancer. 2018 Dec 4;6(1):141. doi: 10.1186/s40425-018-0463-2.

7.

Quantification of bone flare on 18F-NaF PET/CT in metastatic castration-resistant prostate cancer.

Weisman AJ, Harmon SA, Perk TG, Eickhoff J, Choyke PL, Kurdziel KA, Dahut WL, Humm JL, Apolo AB, Larson SM, Morris MJ, Perlman SB, Liu G, Jeraj R.

Prostate Cancer Prostatic Dis. 2019 May;22(2):324-330. doi: 10.1038/s41391-018-0110-5. Epub 2018 Nov 9.

PMID:
30413807
8.

A Randomized, Double-blind, Phase II Trial of PSA-TRICOM (PROSTVAC) in Patients with Localized Prostate Cancer: The Immunotherapy to Prevent Progression on Active Surveillance Study.

Parsons JK, Pinto PA, Pavlovich CP, Uchio E, Kim HL, Nguyen MN, Gulley JL, Jamieson C, Hsu P, Wojtowicz M, Parnes H, Schlom J, Dahut WL, Madan RA, Donahue RN, Chow HS.

Eur Urol Focus. 2018 Sep;4(5):636-638. doi: 10.1016/j.euf.2018.08.016. Epub 2018 Sep 7.

PMID:
30197041
9.

A PDX/Organoid Biobank of Advanced Prostate Cancers Captures Genomic and Phenotypic Heterogeneity for Disease Modeling and Therapeutic Screening.

Beshiri ML, Tice CM, Tran C, Nguyen HM, Sowalsky AG, Agarwal S, Jansson KH, Yang Q, McGowen KM, Yin J, Alilin AN, Karzai FH, Dahut WL, Corey E, Kelly K.

Clin Cancer Res. 2018 Sep 1;24(17):4332-4345. doi: 10.1158/1078-0432.CCR-18-0409. Epub 2018 May 10.

10.

Naming disease states for clinical utility in prostate cancer: a rose by any other name might not smell as sweet.

Armstrong AJ, Antonarakis ES, Taplin ME, Kelly WK, Beltran H, Fizazi K, Dahut WL, Shore N, Slovin S, George D, Carducci MA, Corn P, Danila D, Dreicer R, Heath E, Rathkopf D, Liu G, Nanus D, Stein M, Smith MR, Sternberg C, Wilding G, Nelson PS, Halabi S, Kantoff P, Clarke NW, Evans CP, Heidenreich A, Mottet N, Gleave M, Morris MJ, Scher HI.

Ann Oncol. 2018 Jan 1;29(1):23-25. doi: 10.1093/annonc/mdx648. No abstract available.

11.

Quantitative Assessment of Early [18F]Sodium Fluoride Positron Emission Tomography/Computed Tomography Response to Treatment in Men With Metastatic Prostate Cancer to Bone.

Harmon SA, Perk T, Lin C, Eickhoff J, Choyke PL, Dahut WL, Apolo AB, Humm JL, Larson SM, Morris MJ, Liu G, Jeraj R.

J Clin Oncol. 2017 Aug 20;35(24):2829-2837. doi: 10.1200/JCO.2017.72.2348. Epub 2017 Jun 27.

12.

Management Options for Biochemically Recurrent Prostate Cancer.

Fakhrejahani F, Madan RA, Dahut WL.

Curr Treat Options Oncol. 2017 May;18(5):26. doi: 10.1007/s11864-017-0462-4. Review.

PMID:
28434181
13.

Samarium-153-EDTMP (Quadramet®) with or without vaccine in metastatic castration-resistant prostate cancer: A randomized Phase 2 trial.

Heery CR, Madan RA, Stein MN, Stadler WM, Di Paola RS, Rauckhorst M, Steinberg SM, Marté JL, Chen CC, Grenga I, Donahue RN, Jochems C, Dahut WL, Schlom J, Gulley JL.

Oncotarget. 2016 Oct 18;7(42):69014-69023. doi: 10.18632/oncotarget.10883.

14.

Radium-223 in prostate cancer: emitting the right signals.

Madan RA, Gulley JL, Dahut WL.

Lancet Oncol. 2016 Sep;17(9):1186-7. doi: 10.1016/S1470-2045(16)30248-0. Epub 2016 Jul 26. No abstract available.

15.

Repeatability of Quantitative 18F-NaF PET: A Multicenter Study.

Lin C, Bradshaw T, Perk T, Harmon S, Eickhoff J, Jallow N, Choyke PL, Dahut WL, Larson S, Humm JL, Perlman S, Apolo AB, Morris MJ, Liu G, Jeraj R.

J Nucl Med. 2016 Dec;57(12):1872-1879. Epub 2016 Jul 21.

16.

A Phase II Clinical Trial of TRC105 (Anti-Endoglin Antibody) in Adults With Advanced/Metastatic Urothelial Carcinoma.

Apolo AB, Karzai FH, Trepel JB, Alarcon S, Lee S, Lee MJ, Tomita Y, Cao L, Yu Y, Merino MJ, Madan RA, Parnes HL, Steinberg SM, Rodriguez BW, Seon BK, Gulley JL, Arlen PM, Dawson NA, Figg WD, Dahut WL.

Clin Genitourin Cancer. 2017 Feb;15(1):77-85. doi: 10.1016/j.clgc.2016.05.010. Epub 2016 May 27.

17.

Metabolic syndrome in prostate cancer: impact on risk and outcomes.

Karzai FH, Madan RA, Dahut WL.

Future Oncol. 2016 Aug;12(16):1947-55. doi: 10.2217/fon-2016-0061. Epub 2016 Apr 12. Review.

18.

Prospective Study Evaluating Na18F PET/CT in Predicting Clinical Outcomes and Survival in Advanced Prostate Cancer.

Apolo AB, Lindenberg L, Shih JH, Mena E, Kim JW, Park JC, Alikhani A, McKinney YY, Weaver J, Turkbey B, Parnes HL, Wood LV, Madan RA, Gulley JL, Dahut WL, Kurdziel KA, Choyke PL.

J Nucl Med. 2016 Jun;57(6):886-92. doi: 10.2967/jnumed.115.166512. Epub 2016 Jan 21.

19.

Phase II trial of docetaxel, bevacizumab, lenalidomide and prednisone in patients with metastatic castration-resistant prostate cancer.

Madan RA, Karzai FH, Ning YM, Adesunloye BA, Huang X, Harold N, Couvillon A, Chun G, Cordes L, Sissung T, Beedie SL, Dawson NA, Theoret MR, McLeod DG, Rosner I, Trepel JB, Lee MJ, Tomita Y, Lee S, Chen C, Steinberg SM, Arlen PM, Gulley JL, Figg WD, Dahut WL.

BJU Int. 2016 Oct;118(4):590-7. doi: 10.1111/bju.13412. Epub 2016 Feb 19.

20.

Sorafenib-Induced Eruption Mimicking Erythema Multiforme.

Pichard DC, Cardones AR, Chu EY, Dahut WL, Kong HH.

JAMA Dermatol. 2016 Feb;152(2):227-8. doi: 10.1001/jamadermatol.2015.2930. No abstract available.

21.

Prostate cancer: Charting a course in metastatic castration-sensitive prostate cancer.

Madan RA, Dahut WL.

Nat Rev Urol. 2015 Jul;12(7):368-9. doi: 10.1038/nrurol.2015.144. Epub 2015 Jun 16. No abstract available.

PMID:
26077994
22.

Abiraterone's efficacy confirmed; time to aim higher.

Madan R, Dahut WL.

Lancet Oncol. 2015 Feb;16(2):119-21. doi: 10.1016/S1470-2045(15)70005-7. Epub 2015 Jan 16. No abstract available.

PMID:
25601338
23.

Cutaneous adverse effects associated with the tyrosine-kinase inhibitor cabozantinib.

Zuo RC, Apolo AB, DiGiovanna JJ, Parnes HL, Keen CM, Nanda S, Dahut WL, Cowen EW.

JAMA Dermatol. 2015 Feb;151(2):170-7. doi: 10.1001/jamadermatol.2014.2734.

24.

A phase I study of TRC105 anti-endoglin (CD105) antibody in metastatic castration-resistant prostate cancer.

Karzai FH, Apolo AB, Cao L, Madan RA, Adelberg DE, Parnes H, McLeod DG, Harold N, Peer C, Yu Y, Tomita Y, Lee MJ, Lee S, Trepel JB, Gulley JL, Figg WD, Dahut WL.

BJU Int. 2015 Oct;116(4):546-55. doi: 10.1111/bju.12986. Epub 2015 Jun 8.

25.

Tyrosine kinase inhibitors in the treatment of prostate cancer: taking the next step in clinical development.

Ojemuyiwa MA, Madan RA, Dahut WL.

Expert Opin Emerg Drugs. 2014 Dec;19(4):459-70. doi: 10.1517/14728214.2014.969239. Epub 2014 Oct 25. Review.

PMID:
25345821
26.

Real-world experience with abiraterone.

Dahut WL, Madan RA.

Lancet Oncol. 2014 Oct;15(11):1188-90. doi: 10.1016/S1470-2045(14)70463-2. Epub 2014 Sep 18. No abstract available. Erratum in: Lancet Oncol. 2014 Nov;15(12):e528.

PMID:
25242047
27.

A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: immune correlates.

Jochems C, Tucker JA, Tsang KY, Madan RA, Dahut WL, Liewehr DJ, Steinberg SM, Gulley JL, Schlom J.

Cancer Immunol Immunother. 2014 Apr;63(4):407-18. doi: 10.1007/s00262-014-1524-0. Epub 2014 Feb 11.

28.

Urinary aHGF, IGFBP3 and OPN as diagnostic and prognostic biomarkers for prostate cancer.

Prager AJ, Peng CR, Lita E, McNally D, Kaushal A, Sproull M, Compton K, Dahut WL, Figg WD, Citrin D, Camphausen KA.

Biomark Med. 2013 Dec;7(6):831-41. doi: 10.2217/bmm.13.112.

29.

Angiogenesis inhibitors in the treatment of prostate cancer.

Adesunloye BA, Karzai FH, Dahut WL.

Chem Immunol Allergy. 2014;99:197-215. doi: 10.1159/000353255. Epub 2013 Oct 17. Review.

PMID:
24217611
30.

Phase I study of intraprostatic vaccine administration in men with locally recurrent or progressive prostate cancer.

Gulley JL, Heery CR, Madan RA, Walter BA, Merino MJ, Dahut WL, Tsang KY, Schlom J, Pinto PA.

Cancer Immunol Immunother. 2013 Sep;62(9):1521-31. doi: 10.1007/s00262-013-1448-0. Epub 2013 Jul 9.

31.

Phase II study of satraplatin and prednisone in patients with metastatic castration-resistant prostate cancer: a pharmacogenetic assessment of outcome and toxicity.

Figg WD, Chau CH, Madan RA, Gulley JL, Gao R, Sissung TM, Spencer S, Beatson M, Aragon-Ching J, Steinberg SM, Dahut WL.

Clin Genitourin Cancer. 2013 Sep;11(3):229-37. doi: 10.1016/j.clgc.2013.04.007. Epub 2013 May 17.

32.

Is it time to reevaluate definitive therapy in prostate cancer?

Madan RA, Shah AA, Dahut WL.

J Natl Cancer Inst. 2013 May 15;105(10):683-5. doi: 10.1093/jnci/djt094. Epub 2013 Apr 24. No abstract available.

33.

Phase II clinical trial of cediranib in patients with metastatic castration-resistant prostate cancer.

Dahut WL, Madan RA, Karakunnel JJ, Adelberg D, Gulley JL, Turkbey IB, Chau CH, Spencer SD, Mulquin M, Wright J, Parnes HL, Steinberg SM, Choyke PL, Figg WD.

BJU Int. 2013 Jun;111(8):1269-80. doi: 10.1111/j.1464-410X.2012.11667.x. Epub 2013 Feb 18.

34.

Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.

Madan RA, Mohebtash M, Arlen PM, Vergati M, Rauckhorst M, Steinberg SM, Tsang KY, Poole DJ, Parnes HL, Wright JJ, Dahut WL, Schlom J, Gulley JL.

Lancet Oncol. 2012 May;13(5):501-8. doi: 10.1016/S1470-2045(12)70006-2. Epub 2012 Feb 10.

35.

A pilot study of MUC-1/CEA/TRICOM poxviral-based vaccine in patients with metastatic breast and ovarian cancer.

Mohebtash M, Tsang KY, Madan RA, Huen NY, Poole DJ, Jochems C, Jones J, Ferrara T, Heery CR, Arlen PM, Steinberg SM, Pazdur M, Rauckhorst M, Jones EC, Dahut WL, Schlom J, Gulley JL.

Clin Cancer Res. 2011 Nov 15;17(22):7164-73. doi: 10.1158/1078-0432.CCR-11-0649. Epub 2011 Nov 8.

36.

From clinical trials to clinical practice: therapeutic cancer vaccines for the treatment of prostate cancer.

Madan RA, Aragon-Ching JB, Gulley JL, Dahut WL.

Expert Rev Vaccines. 2011 Jun;10(6):743-53. doi: 10.1586/erv.11.70. Review.

37.

Overcoming chemotherapy resistance in prostate cancer.

Madan RA, Pal SK, Sartor O, Dahut WL.

Clin Cancer Res. 2011 Jun 15;17(12):3892-902. doi: 10.1158/1078-0432.CCR-10-2654.

38.

Population pharmacokinetic analysis of sorafenib in patients with solid tumours.

Jain L, Woo S, Gardner ER, Dahut WL, Kohn EC, Kummar S, Mould DR, Giaccone G, Yarchoan R, Venitz J, Figg WD.

Br J Clin Pharmacol. 2011 Aug;72(2):294-305. doi: 10.1111/j.1365-2125.2011.03963.x.

39.

Hepcidin, anaemia, and prostate cancer.

Tanno T, Rabel A, Alleyne M, Lee YT, Dahut WL, Gulley JL, Miller JL.

BJU Int. 2011 Feb;107(4):678-9. doi: 10.1111/j.1464-410X.2011.10108.x. No abstract available.

40.

A SNP in CYP2C8 is not associated with the development of bisphosphonate-related osteonecrosis of the jaw in men with castrate-resistant prostate cancer.

English BC, Baum CE, Adelberg DE, Sissung TM, Kluetz PG, Dahut WL, Price DK, Figg WD.

Ther Clin Risk Manag. 2010 Nov 19;6:579-83. doi: 10.2147/TCRM.S14303.

41.

Cabazitaxel: a new drug for metastatic prostate cancer.

Bilusic M, Dahut WL.

Asian J Androl. 2011 Mar;13(2):185-6. doi: 10.1038/aja.2010.161. Epub 2010 Dec 13. No abstract available.

42.

An update on androgen deprivation therapy for prostate cancer.

Sharifi N, Gulley JL, Dahut WL.

Endocr Relat Cancer. 2010 Oct 29;17(4):R305-15. doi: 10.1677/ERC-10-0187. Print 2010 Dec. Review.

43.

Therapeutic cancer vaccines in prostate cancer: the paradox of improved survival without changes in time to progression.

Madan RA, Gulley JL, Fojo T, Dahut WL.

Oncologist. 2010;15(9):969-75. doi: 10.1634/theoncologist.2010-0129. Epub 2010 Aug 26.

44.

Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib.

Jain L, Sissung TM, Danesi R, Kohn EC, Dahut WL, Kummar S, Venzon D, Liewehr D, English BC, Baum CE, Yarchoan R, Giaccone G, Venitz J, Price DK, Figg WD.

J Exp Clin Cancer Res. 2010 Jul 14;29:95. doi: 10.1186/1756-9966-29-95.

45.

Novel Androgen Deprivation Therapy (ADT) in the Treatment of Advanced Prostate Cancer.

Aragon-Ching JB, Dahut WL.

Drug Discov Today Ther Strateg. 2010 Jul 1;7(1-2):31-35.

46.

Genetic polymorphisms in XRCC1 associated with radiation therapy in prostate cancer.

Gao R, Price DK, Dahut WL, Reed E, Figg WD.

Cancer Biol Ther. 2010 Jul 1;10(1):13-8.

47.

A phase I clinical study of high dose ketoconazole plus weekly docetaxel for metastatic castration resistant prostate cancer.

Figg WD, Woo S, Zhu W, Chen X, Ajiboye AS, Steinberg SM, Price DK, Wright JJ, Parnes HL, Arlen PM, Gulley JL, Dahut WL.

J Urol. 2010 Jun;183(6):2219-26. doi: 10.1016/j.juro.2010.02.020.

48.

Revisiting the ultimate target of treatment for prostate cancer.

Dahut WL, Madan RA.

Lancet. 2010 Apr 24;375(9724):1409-10. doi: 10.1016/S0140-6736(10)60400-X. Epub 2010 Apr 14. No abstract available.

PMID:
20398924
49.

Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer.

Ning YM, Gulley JL, Arlen PM, Woo S, Steinberg SM, Wright JJ, Parnes HL, Trepel JB, Lee MJ, Kim YS, Sun H, Madan RA, Latham L, Jones E, Chen CC, Figg WD, Dahut WL.

J Clin Oncol. 2010 Apr 20;28(12):2070-6. doi: 10.1200/JCO.2009.25.4524. Epub 2010 Mar 22.

50.

Tumor angiogenesis as an early marker of long-term prostate cancer mortality.

Zhu W, Dahut WL.

Future Oncol. 2010 Mar;6(3):341-5. doi: 10.2217/fon.09.177. No abstract available.

PMID:
20222790

Supplemental Content

Loading ...
Support Center